141 related articles for article (PubMed ID: 21547590)
1. Cerebrovascular events after bevacizumab treatment: an early and severe complication.
Seet RC; Rabinstein AA; Lindell PE; Uhm JH; Wijdicks EF
Neurocrit Care; 2011 Dec; 15(3):421-7. PubMed ID: 21547590
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.
Zuo PY; Chen XL; Liu YW; Xiao CL; Liu CY
PLoS One; 2014; 9(7):e102484. PubMed ID: 25025282
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
Higashide T; Murotani E; Saito Y; Ohkubo S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):603-10. PubMed ID: 22116499
[TBL] [Abstract][Full Text] [Related]
4. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
Khasraw M; Holodny A; Goldlust SA; DeAngelis LM
Ann Oncol; 2012 Feb; 23(2):458-63. PubMed ID: 21543627
[TBL] [Abstract][Full Text] [Related]
5. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
Norden AD; Bartolomeo J; Tanaka S; Drappatz J; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Quant EC; Beroukhim R; Wen PY
J Neurooncol; 2012 Jan; 106(1):121-5. PubMed ID: 21706358
[TBL] [Abstract][Full Text] [Related]
6. Cerebrovascular complications of the use of the "crack" form of alkaloidal cocaine.
Levine SR; Brust JC; Futrell N; Ho KL; Blake D; Millikan CH; Brass LM; Fayad P; Schultz LR; Selwa JF
N Engl J Med; 1990 Sep; 323(11):699-704. PubMed ID: 2388668
[TBL] [Abstract][Full Text] [Related]
7. Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.
Tlemsani C; Mir O; Psimaras D; Vano YA; Ducreux M; Escudier B; Rousseau B; Loirat D; Ceccaldi B; André T; Goldwasser F; Ricard D
Eur J Cancer; 2016 Oct; 66():75-82. PubMed ID: 27529757
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab: radiation combination produces restricted diffusion on brain MRI.
Hesselink JR; Barkovich MJ; Seibert TM; Farid N; Muller KA; Murphy KT; Kesari S
CNS Oncol; 2014; 3(5):329-35. PubMed ID: 25363005
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience.
Sadraei NH; Dahiya S; Chao ST; Murphy ES; Osei-Boateng K; Xie H; Suh JH; Peereboom DM; Stevens GH; Ahluwalia MS
Am J Clin Oncol; 2015 Jun; 38(3):304-10. PubMed ID: 23799286
[TBL] [Abstract][Full Text] [Related]
10. Intracranial hemorrhage in patients treated with bevacizumab: report of two cases.
Nishimura T; Furihata M; Kubo H; Tani M; Agawa S; Setoyama R; Toyoda T
World J Gastroenterol; 2011 Oct; 17(39):4440-4. PubMed ID: 22110272
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
12. Transient global amnesia after cerebral angiography with iohexol.
Juni J; Morera J; Láinez JM; Escudero J; Ferrer C; Sancho J
Neuroradiology; 1992; 34(2):141-3. PubMed ID: 1603313
[TBL] [Abstract][Full Text] [Related]
13. [Cerebral angiitis or central side effects after lumbar myelography (with intracerebral vascular spasm)].
May A; Faiss J; Keidel M; Schwarz M; Weiller C
Nervenarzt; 1994 Feb; 65(2):125-7. PubMed ID: 8164765
[TBL] [Abstract][Full Text] [Related]
14. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
15. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and central nervous system (CNS) hemorrhage.
Letarte N; Bressler LR; Villano JL
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1561-5. PubMed ID: 23564377
[TBL] [Abstract][Full Text] [Related]
18. Acute and severe acne in a patient treated with bevacizumab.
Molina-Ruiz AM; Domine M; Requena L
Int J Dermatol; 2013 Apr; 52(4):486-90. PubMed ID: 23432695
[TBL] [Abstract][Full Text] [Related]
19. Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity.
Futterer SF; Nemeth AJ; Grimm SA; Ragin AB; Chandler JP; Muro K; Marymont MH; Raizer JJ
J Neurooncol; 2014 May; 118(1):147-53. PubMed ID: 24574050
[TBL] [Abstract][Full Text] [Related]
20. Pretruncal subarachnoid hemorrhage and high cerebral blood flow velocities with bevacizumab therapy.
Baizabal-Carvallo JF; Alonso-Juárez M; Salas I
Clin Neuropharmacol; 2010; 33(5):268-9. PubMed ID: 20864839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
